1. Mendell, Jerry R, Pozsgai, Eric R, Lewis, Sarah, Stevenson, Herb, Rodino-Klapac, Louise R. 2024. Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial results. In Nature medicine, 30, 199-206. doi:10.1038/s41591-023-02730-9. https://pubmed.ncbi.nlm.nih.gov/38177855/
2. Magri, Francesca, Zanotti, Simona, Salani, Sabrina, Comi, Giacomo Pietro, Ronchi, Dario. 2022. Antisense Morpholino-Based In Vitro Correction of a Pseudoexon-Generating Variant in the SGCB Gene. In International journal of molecular sciences, 23, . doi:10.3390/ijms23179817. https://pubmed.ncbi.nlm.nih.gov/36077211/
3. Vainzof, Mariz, Souza, Lucas S, Gurgel-Giannetti, Juliana, Zatz, Mayana. 2021. Sarcoglycanopathies: an update. In Neuromuscular disorders : NMD, 31, 1021-1027. doi:10.1016/j.nmd.2021.07.014. https://pubmed.ncbi.nlm.nih.gov/34404573/
4. Ababneh, Nidaa A, Barham, Raghda, Al-Kurdi, Ban, El-Khateeb, Mohammed, Awidi, Abdalla. 2021. Generation of an induced pluripotent stem cell (iPSC) line (JUCTCi017-A) from a patient with limb-girdle muscular dystrophy (LGMD) due to a homozygous p.Lue287Ser fs14* mutation in the SGCB gene. In Stem cell research, 54, 102358. doi:10.1016/j.scr.2021.102358. https://pubmed.ncbi.nlm.nih.gov/34087734/
5. Li, Chengcheng, Wilborn, Jackson, Pittman, Sara, Weihl, Conrad C, Haller, Gabe. 2023. Comprehensive functional characterization of SGCB coding variants predicts pathogenicity in limb-girdle muscular dystrophy type R4/2E. In The Journal of clinical investigation, 133, . doi:10.1172/JCI168156. https://pubmed.ncbi.nlm.nih.gov/37317968/
6. Pozsgai, E R, Griffin, D A, Heller, K N, Mendell, J R, Rodino-Klapac, L R. 2015. β-Sarcoglycan gene transfer decreases fibrosis and restores force in LGMD2E mice. In Gene therapy, 23, 57-66. doi:10.1038/gt.2015.80. https://pubmed.ncbi.nlm.nih.gov/26214262/
智鼠故事 
